Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Histotripsy for Renal Cell Carcinoma (HRCC)

11. november 2026 oppdatert av: Matthew Kin Liang Chiu, The University of Hong Kong

Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need

The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.

Studieoversikt

Detaljert beskrivelse

Study Design and Methodology

This study will enrol 15 patients with localised or metastatic renal cell carcinoma. Patients will be identified from clinic, and undergo a comprehensive evaluation, including imaging studies and laboratory tests, to confirm the diagnosis and assess their eligibility for histotripsy.

Procedure

Histotripsy will be performed by dedicated team of oncologist, urologist and radiologist who have undergone accredited training on Histotripsy aiming to achieve the best clinical outcomes and ensure patient safety. Patients are typically placed under general anaesthesia (GA) or monitored anaesthesia care (MAC) with real-time monitoring. The component of the Histotripsy machine that generates sound waves is positioned within a soft, flexible membrane filled with specially treated water, which rests on the patient's abdomen and facilitates the transmission of sound waves to the targeted tissue. The procedure will be delivered in a single session or multiple sessions by ultrasound, depending on the size and location of tumours.

Assessment

Patients will be invited to complete a questionnaire for pain score assessment before and after histotripsy.

Blood samples will be collected for clinical evaluation and laboratory tests at baseline, followed by 1-day, 30-day, 60-day, and 90-day after histotripsy, aligned with existing feasibility and trial schedules. Blood tests and cellular analysis such as complete blood profile, liver and renal function tests, tumour markers, immune markers and biomarkers etc. will be performed each time. Patients will be asked for consent for 15ml blood collection for the cellular analysis.

Serial post-histotripsy imaging (CT/MRI) will also be arranged. Imaging within 36-hour after histotripsy will be proceeded to confirm the ablation zone and assess complications. Post-procedure imaging at 1-, 3-, and 6-month will help to capture the sustainability of treatment effect, then per standard of care thereafter.

Admission and follow-up

Similar to other minimal invasive treatments, patients will be admitted one day prior, or on the day of procedure. After the procedure of histotripsy, patients may experience some discomfort in the treated area, but patients can often return to normal activities quickly. They could be discharged in few hours, or the next day after procedure depending on clinical conditions.

After discharge, follow-up consultations and assessments such as regular imaging and blood tests will be arranged accordingly.

Potential risk and discomfort

Blood drawn for laboratory tests can cause bruising at or near the site where the needle enters the vein and thus increase the risk of infection. Risks related to imaging scans will be explained prior to the procedures by the related doctors or medical professionals.

Procedure risk related to Histotripsy includes skin erythema or superficial burn injury, infection, bleeding, renal dysfunction, and abdominal wall injury or burn. Adverse post treatment event includes bleeding, infection, damage to surrounding structures etc. The medical team will monitor closely and response promptly.

Short-term effects

  • Mild pain or soreness that usually responds to oral pain medication
  • Low-grade fever and flu-like symptoms that typically resolve within 48 hours
  • Temporary skin redness at the treatment site
  • Mild abdominal discomfort
  • Temporary changes in renal function tests
  • Possible nausea or fatigue
  • Transient haematuria

Potential serious complications

  • Temporary decrease in kidney function
  • Potential damage to surrounding organs (liver, lung, bowel, or stomach)
  • Severe pain
  • Need for extended hospital stay or additional treatment for serious complications
  • Skin ulcer / necrosis requiring interventions
  • Vascular thrombosis / dissection

Long-term complications

• Currently, there is no known long-term side effects from Histotripsy treatment. Ongoing research aims to evaluate the long-term outcomes.

In the event of complications arising from the study treatment, patients will be treated accordingly or referred for standard treatment and care.

Statistical analysis

Analysis will be performed for the 15 participants recruited, with basic demography (age, sex, medical history etc.), clinical evaluation, laboratory tests, imaging, treatment outcome with associated complication.

DATA AND BIOLOGICAL SAMPLES HANDLING

Patients will be invited to register on the Histotripsy (HistoSonics○R) Registry in Gleneagles Hospital Hong Kong for data collection. Collected personal and study data will be anonymised and stored in a password protected, encrypted database with the principal investigator and delegated staff in the long run. The principal investigator will be responsible for the safekeeping. Only investigators and delegated staff can have right to gain access to the data. All collected data and biological samples will be stored permanently for future review in histotripsy related research. Unused biological samples will be destroyed and discarded upon request, however, the results will remain a part of the overall research data if part of the sample has been proceeded.

Consent

Written voluntary consents will be obtained after full explanation of the study to patients before agreement of the histotripsy procedure.

Conflicts of interests

All investigators and funding bodies have no financial interests in the study.

Research ethics

The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Patient data protection.

Studietype

Intervensjonell

Registrering (Antatt)

15

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Professor Matthew Kin-liang CHIU, PhD
  • Telefonnummer: +852 22554352
  • E-post: mklc2@hku.hk

Studiesteder

      • Hong Kong, Hong Kong
        • Rekruttering
        • Gleneagles Hospital Hong Kong
        • Ta kontakt med:
          • Professor Matthew Kin-liang CHIU, PhD
          • Telefonnummer: +852 22554352
          • E-post: mklc2@hku.hk
        • Underetterforsker:
          • Wing Hang Vince Lau, MBBS, FHKCR, FHKAM
        • Underetterforsker:
          • Chi-Yan Albert Chan, MBBS, MS, FRCSEd, FCSHK, FHKAM
        • Underetterforsker:
          • Justin Christopher Ng, MBBChBAO, LMCHK, MMED, FRCR
        • Underetterforsker:
          • Pei Wayne Lam, MBBS, LMCHK, FRCSed, FCSHK
        • Underetterforsker:
          • Cho Wing Bryan Li, MBBS, MRCP, FHKCP, FHKAM
        • Underetterforsker:
          • Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
        • Underetterforsker:
          • Lok Hei Clarence Leung, MBChB, FRCSEd, FCSHK, FHKAM
        • Underetterforsker:
          • Hin Kay John Ngan, MBBS, FHKCS, FHKAM, FRCSE

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years old
  • Fit for general anaesthesia
  • Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
  • With or without distant metastases
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2
  • Tumour visible and targetable by ultrasound with acceptable acoustic windows
  • Adequate hematologic, hepatic, and renal function (eGFR ≥45mL/min, ≤14 days prior to the planned index procedure date).

Exclusion Criteria:

  • Refusal to take part in clinical trial
  • Not fit for general anaesthesia
  • Poor general condition with limited life expectancy
  • Uncontrolled coagulopathy
  • The treatment of the tumour will not allow for an adequate margin as determined by the investigator

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison System

Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To assess efficacy
Tidsramme: 90 days post procedure

Successful treatment percentage at 90 days on MRI/CT post-procedure

90 days post procedure
To assess treatment safety
Tidsramme: At 30 days

Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher

At 30 days

Sekundære resultatmål

Resultatmål
Tidsramme
Pain score assessment before and after histotripsy
Tidsramme: At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. oktober 2026

Primær fullføring (Antatt)

30. oktober 2028

Studiet fullført (Antatt)

30. oktober 2029

Datoer for studieregistrering

Først innsendt

17. september 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere